Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $7.67 Average Price Target from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.67.

Several research analysts have weighed in on TSHA shares. BTIG Research lowered shares of Taysha Gene Therapies from a “buy” rating to a “neutral” rating in a research note on Thursday, February 2nd. Robert W. Baird dropped their price objective on shares of Taysha Gene Therapies from $10.00 to $6.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Truist Financial dropped their price objective on shares of Taysha Gene Therapies from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, March 29th. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 29th.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC increased its position in shares of Taysha Gene Therapies by 86.2% during the 4th quarter. Nantahala Capital Management LLC now owns 2,999,765 shares of the company’s stock worth $6,779,000 after purchasing an additional 1,388,943 shares in the last quarter. Artal Group S.A. increased its position in shares of Taysha Gene Therapies by 38.4% during the 4th quarter. Artal Group S.A. now owns 1,440,882 shares of the company’s stock worth $3,256,000 after purchasing an additional 400,000 shares in the last quarter. Laurion Capital Management LP increased its position in shares of Taysha Gene Therapies by 192.0% during the 4th quarter. Laurion Capital Management LP now owns 1,292,600 shares of the company’s stock worth $2,921,000 after purchasing an additional 850,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Taysha Gene Therapies by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock worth $6,599,000 after purchasing an additional 128,517 shares in the last quarter. Finally, Alphabet Inc. bought a new stake in Taysha Gene Therapies during the 3rd quarter worth about $1,237,000. Institutional investors and hedge funds own 45.12% of the company’s stock.

Taysha Gene Therapies Stock Up 5.7 %

NASDAQ TSHA opened at $0.78 on Friday. The company has a debt-to-equity ratio of 40.01, a current ratio of 1.33 and a quick ratio of 1.54. The company’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.41. Taysha Gene Therapies has a 12 month low of $0.61 and a 12 month high of $5.09. The company has a market capitalization of $50.16 million, a P/E ratio of -0.28 and a beta of 1.17.

Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) last released its quarterly earnings results on Tuesday, March 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.58). The firm had revenue of $2.50 million for the quarter. Equities research analysts expect that Taysha Gene Therapies will post -0.87 earnings per share for the current fiscal year.

About Taysha Gene Therapies

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.